Related Experiment Video
Updated: Jun 12, 2026
High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
Published on: July 17, 2014
Structure-guided design of a PfCyRPA-based vaccine against blood-stage malaria
Nawsad Alam1,2, Clare Wolfle1,2, Egle Butkeviciute1,2
1Department of Biochemistry, Dorothy Crowfoot Hodgkin Building, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK.
Insights
Developing new malaria vaccines is crucial. A novel Plasmodium falciparum Circumsporozoite protein receptor (PfCyRPA) epitope mimic, PfCyRPA-EM, shows enhanced parasite growth inhibition and stability, making it a promising malaria vaccine candidate.
Area of Science:
- Immunology
- Parasitology
- Vaccine Development
Background:
- Malaria remains a significant global health challenge, necessitating effective vaccines.
- Plasmodium falciparum erythrocyte invasion involves the PfPCRCR complex, with PfRH5 and PfCyRPA being key targets for blood-stage malaria vaccines.
- PfCyRPA elicits parasite growth-inhibitory antibodies, but improved immunogens are needed for enhanced efficacy.
Purpose of the Study:
- To design and generate improved PfCyRPA-based immunogens for malaria vaccine development.
- To create a thermostable, correctly folded epitope mimic of PfCyRPA, focusing on key antibody-binding regions.
Main Methods:
- Structure-guided design was employed to create PfCyRPA-EM, mimicking critical epitopes (blades 1 and 2) of PfCyRPA.
- Direct nanoparticle coupling was used to fuse PfCyRPA-EM with I53-50 nanoparticles.
- Pre-clinical models were used to evaluate the immunogenicity and efficacy of the novel immunogen.
Main Results:
- PfCyRPA-EM elicited antibodies with significantly higher parasite growth-inhibitory activity compared to native PfCyRPA.
- The engineered immunogen, PfCyRPA-EM, demonstrated enhanced thermostability.
- Improved expression of PfCyRPA-EM as an I53-50 nanoparticle fusion was achieved.
Conclusions:
- PfCyRPA-EM represents a promising malaria vaccine candidate due to its enhanced efficacy and stability.
- The structure-guided design approach yielded a superior immunogen for potential clinical development.
- This improved immunogen could be valuable for malaria vaccine strategies, either alone or in combination with other antigens.
Abstract:
Effective vaccines against malaria are urgently required. All components of the PfPCRCR complex are essential for erythrocyte invasion by Plasmodium falciparum and are potential vaccine immunogens against blood-stage malaria. Of these, PfRH5 has progressed furthest in clinical development, while PfCyRPA also induces parasite growth-inhibitory antibodies. Here, we used direct nanoparticle coupling and structure-guided design to generate improved PfCyRPA-based immunogens. PfCyRPA is a six-bladed β-propeller. Blades 1 and 2 are exposed in the PfPCRCR complex and contain the epitopes of the most potent known growth-inhibitory antibodies. We therefore performed structure-guided design to generate a correctly folded, thermostable epitope mimic, PfCyRPA-EM, containing blades 1 and 2. In a pre-clinical model, PfCyRPA-EM elicited antibodies that inhibited parasite growth at lower concentrations than those elicited by PfCyRPA. In addition, the higher thermostability of PfCyRPA-EM and its improved expression as an I53-50 nanoparticle fusion make it well-suited for clinical development, alone or with other immunogens.
